phentermine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 2140 | 122-09-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.19 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 2 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 4, 1959 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cholecystitis chronic | 172.57 | 17.09 | 58 | 6772 | 10303 | 63471889 |
| Gallbladder disorder | 75.50 | 17.09 | 38 | 6792 | 18804 | 63463388 |
| Emotional distress | 73.53 | 17.09 | 45 | 6785 | 32504 | 63449688 |
| Injury | 71.93 | 17.09 | 61 | 6769 | 73186 | 63409006 |
| Arteriospasm coronary | 65.19 | 17.09 | 22 | 6808 | 3946 | 63478246 |
| Carotid artery dissection | 64.92 | 17.09 | 12 | 6818 | 172 | 63482020 |
| Anxiety | 64.72 | 17.09 | 97 | 6733 | 217444 | 63264748 |
| Drug abuse | 62.35 | 17.09 | 56 | 6774 | 72462 | 63409730 |
| Phospholipidosis | 52.78 | 17.09 | 10 | 6820 | 165 | 63482027 |
| Psoriasis | 50.17 | 17.09 | 54 | 6776 | 86903 | 63395289 |
| Cholelithiasis | 48.13 | 17.09 | 39 | 6791 | 43886 | 63438306 |
| Subarachnoid haemorrhage | 43.54 | 17.09 | 24 | 6806 | 14259 | 63467933 |
| Completed suicide | 37.72 | 17.09 | 61 | 6769 | 145612 | 63336580 |
| Dermatitis atopic | 34.28 | 17.09 | 18 | 6812 | 9706 | 63472486 |
| Deep vein thrombosis | 33.28 | 17.09 | 43 | 6787 | 83757 | 63398435 |
| Anhedonia | 32.24 | 17.09 | 18 | 6812 | 10956 | 63471236 |
| Encephalomalacia | 32.19 | 17.09 | 8 | 6822 | 485 | 63481707 |
| Spinal cord infarction | 31.58 | 17.09 | 7 | 6823 | 257 | 63481935 |
| Stress cardiomyopathy | 29.13 | 17.09 | 16 | 6814 | 9434 | 63472758 |
| Product dose omission issue | 26.85 | 17.09 | 70 | 6760 | 234243 | 63247949 |
| Device dislocation | 26.42 | 17.09 | 22 | 6808 | 25683 | 63456509 |
| Biliary dyskinesia | 25.58 | 17.09 | 10 | 6820 | 2719 | 63479473 |
| Colitis ischaemic | 24.67 | 17.09 | 15 | 6815 | 10693 | 63471499 |
| Renal vein thrombosis | 23.64 | 17.09 | 6 | 6824 | 396 | 63481796 |
| Drug intolerance | 23.06 | 17.09 | 3 | 6827 | 308658 | 63173534 |
| Depression | 22.81 | 17.09 | 59 | 6771 | 196433 | 63285759 |
| Pseudomembranous colitis | 20.96 | 17.09 | 9 | 6821 | 3103 | 63479089 |
| Subacute cutaneous lupus erythematosus | 18.99 | 17.09 | 8 | 6822 | 2635 | 63479557 |
| Pain | 18.86 | 17.09 | 140 | 6690 | 740488 | 62741704 |
| Medical device discomfort | 17.81 | 17.09 | 7 | 6823 | 1932 | 63480260 |
| Cholecystitis acute | 17.57 | 17.09 | 11 | 6819 | 8249 | 63473943 |
| Amyloidosis | 17.49 | 17.09 | 6 | 6824 | 1129 | 63481063 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 59.19 | 27.03 | 36 | 955 | 99060 | 34856880 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cholecystitis chronic | 159.70 | 18.72 | 50 | 6140 | 9856 | 79728342 |
| Drug abuse | 95.93 | 18.72 | 88 | 6102 | 162603 | 79575595 |
| Injury | 77.40 | 18.72 | 57 | 6133 | 77439 | 79660759 |
| Emotional distress | 68.06 | 18.72 | 41 | 6149 | 39928 | 79698270 |
| Arteriospasm coronary | 64.66 | 18.72 | 23 | 6167 | 6693 | 79731505 |
| Gallbladder disorder | 61.41 | 18.72 | 30 | 6160 | 19310 | 79718888 |
| Carotid artery dissection | 60.89 | 18.72 | 12 | 6178 | 345 | 79737853 |
| Completed suicide | 56.97 | 18.72 | 82 | 6108 | 245685 | 79492513 |
| Phospholipidosis | 53.05 | 18.72 | 10 | 6180 | 226 | 79737972 |
| Psoriasis | 46.10 | 18.72 | 45 | 6145 | 89542 | 79648656 |
| Anxiety | 43.68 | 18.72 | 73 | 6117 | 248439 | 79489759 |
| Stress cardiomyopathy | 43.67 | 18.72 | 20 | 6170 | 11146 | 79727052 |
| Subarachnoid haemorrhage | 38.82 | 18.72 | 24 | 6166 | 24441 | 79713757 |
| Deep vein thrombosis | 38.21 | 18.72 | 47 | 6143 | 120872 | 79617326 |
| Cholelithiasis | 38.00 | 18.72 | 32 | 6158 | 52632 | 79685566 |
| Product dose omission issue | 34.84 | 18.72 | 66 | 6124 | 247471 | 79490727 |
| Pain | 31.02 | 18.72 | 122 | 6068 | 703680 | 79034518 |
| Device dislocation | 30.26 | 18.72 | 21 | 6169 | 25949 | 79712249 |
| Dermatitis atopic | 30.13 | 18.72 | 15 | 6175 | 10041 | 79728157 |
| Spinal cord infarction | 27.88 | 18.72 | 7 | 6183 | 616 | 79737582 |
| Encephalomalacia | 27.46 | 18.72 | 8 | 6182 | 1233 | 79736965 |
| Cardio-respiratory arrest | 26.25 | 18.72 | 37 | 6153 | 108473 | 79629725 |
| Respiratory arrest | 26.08 | 18.72 | 27 | 6163 | 57523 | 79680675 |
| Toxicity to various agents | 25.33 | 18.72 | 81 | 6109 | 421459 | 79316739 |
| Anhedonia | 24.61 | 18.72 | 15 | 6175 | 14883 | 79723315 |
| Colitis ischaemic | 24.19 | 18.72 | 15 | 6175 | 15344 | 79722854 |
| Renal vein thrombosis | 23.50 | 18.72 | 6 | 6184 | 565 | 79737633 |
| Biliary dyskinesia | 21.81 | 18.72 | 8 | 6182 | 2537 | 79735661 |
| Device breakage | 20.91 | 18.72 | 12 | 6178 | 10663 | 79727535 |
| Subacute cutaneous lupus erythematosus | 19.20 | 18.72 | 8 | 6182 | 3553 | 79734645 |
| Pseudomembranous colitis | 19.07 | 18.72 | 9 | 6181 | 5365 | 79732833 |
| Scleroderma | 18.85 | 18.72 | 9 | 6181 | 5501 | 79732697 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AA01 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| ATC | A08AA51 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| FDA PE | N0000175372 | Appetite Suppression |
| FDA EPC | N0000175423 | Sympathomimetic Amine Anorectic |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D019440 | Anti-Obesity Agents |
| MeSH PA | D001067 | Appetite Depressants |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| CHEBI has role | CHEBI:35337 | analeptic |
| CHEBI has role | CHEBI:35470 | central nervous system agents |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:37962 | adrenergic agents |
| CHEBI has role | CHEBI:48560 | dopaminergic agents |
| FDA PE | N0000175651 | Increased Sympathetic Activity |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Low blood pressure | indication | 45007003 | |
| Obesity | indication | 414916001 | DOID:9970 |
| Prevention of Hypotension During Spinal Anesthesia | indication | ||
| Hypotension Secondary to Spinal Anesthesia | indication | ||
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Alcoholism | contraindication | 7200002 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Feeling agitated | contraindication | 24199005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
| Secondary glaucoma | contraindication | 95717004 | |
| Angina pectoris | contraindication | 194828000 | |
| Edema | contraindication | 267038008 | |
| Syncope | contraindication | 271594007 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.92 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 11.25MG BASE;69MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8895057 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 11.25MG BASE;69MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9011906 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 15MG BASE;92MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8895057 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 15MG BASE;92MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9011906 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 3.75MG BASE;23MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8895057 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 3.75MG BASE;23MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9011906 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 7.5MG BASE;46MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8895057 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 7.5MG BASE;46MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9011906 | June 9, 2028 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX) |
| EQ 11.25MG BASE;69MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580299 | June 14, 2029 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY |
| EQ 15MG BASE;92MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580299 | June 14, 2029 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY |
| EQ 3.75MG BASE;23MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580299 | June 14, 2029 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY |
| EQ 7.5MG BASE;46MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580299 | June 14, 2029 | FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 11.25MG BASE;69MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 24, 2025 | NEW PATIENT POPULATION |
| EQ 15MG BASE;92MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 24, 2025 | NEW PATIENT POPULATION |
| EQ 3.75MG BASE;23MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 24, 2025 | NEW PATIENT POPULATION |
| EQ 7.5MG BASE;46MG | QSYMIA | VIVUS | N022580 | July 17, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 24, 2025 | NEW PATIENT POPULATION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.80 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019891 | VUID |
| N0000147976 | NUI |
| D05458 | KEGG_DRUG |
| 1197-21-3 | SECONDARY_CAS_RN |
| 4018166 | VANDF |
| 4018167 | VANDF |
| 4019891 | VANDF |
| C0031447 | UMLSCUI |
| CHEBI:8080 | CHEBI |
| CHEMBL1574 | ChEMBL_ID |
| DB00191 | DRUGBANK_ID |
| CHEMBL1200912 | ChEMBL_ID |
| D010645 | MESH_DESCRIPTOR_UI |
| 4771 | PUBCHEM_CID |
| 1064 | INN_ID |
| 7269 | IUPHAR_LIGAND_ID |
| C045TQL4WP | UNII |
| 221138 | RXNORM |
| 1294 | MMSL |
| 41147 | MMSL |
| 5278 | MMSL |
| 5279 | MMSL |
| d00806 | MMSL |
| 001864 | NDDF |
| 001865 | NDDF |
| 001866 | NDDF |
| 373343009 | SNOMEDCT_US |
| 426428004 | SNOMEDCT_US |
| 53480001 | SNOMEDCT_US |
| 6394006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0644 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0647 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5000 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-0597 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-0597 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1308 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1308 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1310 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1310 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1366 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1398 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1438 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1438 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1445 | TABLET | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1445 | TABLET | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1742 | CAPSULE | 15 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1742 | CAPSULE | 15 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1743 | CAPSULE | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1743 | CAPSULE | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-098 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-099 | CAPSULE | 15 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-116 | TABLET | 37.50 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-552 | TABLET | 30 mg | ORAL | ANDA | 31 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-592 | CAPSULE | 37.50 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-593 | CAPSULE | 30 mg | ORAL | ANDA | 19 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-602 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-620 | CAPSULE | 30 mg | ORAL | ANDA | 9 sections |
| LOMAIRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-001 | TABLET | 8 mg | ORAL | ANDA | 17 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-025 | TABLET | 37.50 mg | ORAL | ANDA | 25 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-026 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |